Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15233019 | 0.91 | HDAC1 (0.41) | HDAC1HDAC2KAT2BHDAC3HDAC8 | |
| SCHEMBL18804475 | 0.89 | GRIN2B (0.39) | TAAR1HDAC1HDAC2GRIN2BIDO1 | |
| SCHEMBL18804472 | 0.88 | GRIN2B (0.38) | TAAR1HDAC1HDAC2GRIN2BIDO1 | |
| SCHEMBL13437571 | 0.87 | TRPA1 (0.43) | HDAC1HDAC2GRIN2BIDO1GAA | |
| SCHEMBL22504876 | 0.87 | TRPA1 (0.43) | HDAC1HDAC2GRIN2BIDO1GAA | |
| Benzene SCHEMBL27800821 | 0.87 | TRPA1 (0.43) | HDAC1HDAC2GRIN2BIDO1GAA | |
| SCHEMBL14437648 | 0.86 | HDAC1 (0.36) | TAAR1HDAC1HDAC2GRIN2BIDO1 | |
| SCHEMBL14189703 | 0.84 | HDAC3 (0.45) | HDAC1HDAC2GAAKAT2BHDAC3 | |
| SCHEMBL24437513 | 0.82 | HRH3 (0.56) | TAAR1HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL17469523 | 0.82 | HDAC3 (0.43) | TAAR1HDAC1HDAC2HDAC3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101397277-A | Method for synthesizing aminomethyl biphenyl tetrazole and salt thereof, intermediate and synthetic method thereof | LIANHE CHEMICAL TECHNOLOGY CO (CN) | 2009-04-01 | — | — | CN | claimed |
| CN-115974847-B | 3- (1, 2, 3-Triazole-4-yl) tetrahydroquinazoline-2, 4-dione derivative, and preparation method and application thereof | 中国药科大学 | 2024-12-20 | — | — | CN | disclosed |
| CN-119101052-A | Matrine-triazole derivative and synthesis method thereof | 吉林医药学院 | 2024-12-10 | — | — | CN | disclosed |
| CN-118994003-A | 2-Oxo subunit-1H-quinoline-4-formic acid derivative, preparation method and application thereof | 中国药科大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-115974847-A | 3- (1,2,3-triazole-4-yl) tetrahydroquinazoline-2,4-diketone derivative and preparation method and application thereof | 中国药科大学 | 2023-04-18 | — | — | CN | disclosed |
| US-9290485-B2 | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| US-9290485-B2 | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| EP-2601189-B1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | NOVARTIS AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| CN-101397277-B | Synthesis method of aminomethyl biphenyl tetrazole and salt thereof, intermediate thereof and synthesis method of intermediate | LIANHE CHEMICAL TECHNOLOGY CO LTD | 2012-04-18 | — | — | CN | disclosed |
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | NOVARTIS AG (CH) | 2012-02-09 | — | — | US | disclosed |
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | NOVARTIS AG (CH) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017020-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | NOVARTIS AG (CH) | 2012-02-09 | — | — | WO | disclosed |
| CN-101397277-A | Method for synthesizing aminomethyl biphenyl tetrazole and salt thereof, intermediate and synthetic method thereof | LIANHE CHEMICAL TECHNOLOGY CO (CN) | 2009-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | TPMT, REN, PNMT | TAAR1 1165/4885HDAC1 305/4885HDAC2 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.